The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
6 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $8,840,541 in first-year total cost, median $1,394,542.
Most frequent study sections
- Special Emphasis Panel[ZCA1 RPRB-6 (J2)]6
Most frequent institutions
- ENSPECTRA HEALTH, INC.1
- FOCAL MEDICAL, INC.1
- IMCARE BIOTECH, INC.1
- PRODA BIOTECH, LLC1
- QUADRIGA BIOSCIENCES, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2022 | Development of a protein drug for pancreatic cancer treatment2U44CA217482-04 | LIU, ZHI-REN | PRODA BIOTECH, LLC, GA | $962,484 | ZCA1 |
| 2021 | Implantable iontophoresis chemotherapy delivery device for direct infusion ofgemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial2R44CA224460-04 | DAUNCH, WILLIAM ANDREW | FOCAL MEDICAL, INC., NC | $2,000,000 | ZCA1 |
| 2021 | Noninvasive multiphoton imaging of subcellular structures with color contrast for rapid detection of skin cancers2R44CA221591-03 | SANCHEZ, GABRIEL NESTOR | ENSPECTRA HEALTH, INC., CA | $1,968,512 | ZCA1 |
| 2021 | A novel diagnostic Kit for Hepatocellular Carcinoma2R44CA165314-05A1 | LU, XUANYONG | IMCARE BIOTECH, INC., PA | $1,420,847 | ZCA1 |
| 2021 | Phase 1b/2a Trial of QBS-72S for the Treatment of Newly Diagnosed Glioblastoma Multiforme in Patients with Unmethylated MGMT Promoters2R44CA174129-04 | RINGOLD, GORDON M | QUADRIGA BIOSCIENCES, INC., CA | $1,368,236 | ZCA1 |
| 2021 | PET Enabled Y-90 Microspheres for Radioembolization of Liver Tumors2R44CA165898-04A1 | PENG, YONGREN BENJAMIN | XL SCI-TECH, INC., WA | $1,120,462 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.